The surface of tumor‐derived sEV is enriched with specific proteins compared to healthy controls (HC).[14, 15, 16] For example, GPC1‐ and EphA2‐positive sEV exhibit high specificity and sensitivity in distinguishing PDAC from healthy controls and patients with other diseases.[17, 18, 19, 20] These tumor‐specific markers can potentially overcome the limitations of CA 19‐9, offering a more sensitive and specific diagnostic tool for PDAC. Here, EPHA2 is linked to neoplasm.